ADAGRASIB FOR PATIENTS WITH ADVANCED LUNG CANCER WITH KRAS G12C MUTATION
Adagrasib is a KRAS G12C mutation inhibitor that has been studied for the past several years in patients with these mutations. This drug is similar to Sotorasib, which is FDA approved and available for use. Adagrasib appears to have good efficacy in a subset of patients with non-small cell lung cancer with the G12C mutation […]
ADAGRASIB FOR PATIENTS WITH ADVANCED LUNG CANCER WITH KRAS G12C MUTATION Read More »
